55 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
; and/or (b) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, In addition … , if Consultant is an individual and Consultant files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Consultant may
8-K
EX-10.2
OCUP
Ocuphire Pharma Inc
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
that would result in any application of any law other than the law of the State of Delaware. For purposes of any action, lawsuit or other proceedings
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
(including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company
8-K/A
EX-10.1
aeza 2dqu16
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
km88de
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B3
macb263v
2 Oct 20
Prospectus supplement
9:25am
S-4/A
l1v48ts
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm
S-4/A
EX-10.45
3mitb3x 2p
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm
8-K
EX-10.1
nzb87rxcj0ijk9qwnyhq
1 Jul 20
Entry into a Material Definitive Agreement
8:37am
425
EX-10.1
ygjhimd1zyssi ix8
1 Jul 20
Business combination disclosure
8:35am
8-K
EX-10.4
llzb4qql359o0tv
19 Jun 20
Rexahn and Ocuphire Enter into Definitive Merger Agreement
9:02am
425
EX-10.4
y6m1089tfe8qr21
19 Jun 20
Business combination disclosure
9:00am